Banque Pictet Cie SA Decreases Stake in uniQure - Defense World
QURE Stock | USD 5.97 0.05 0.83% |
About 67% of Uniqure NV's investor base is looking to short. The analysis of the overall investor sentiment regarding Uniqure NV suggests that many traders are alarmed. The current market sentiment, together with Uniqure NV's historical and current headlines, can help investors time the market. In addition, many technical investors use Uniqure NV stock news signals to limit their universe of possible portfolio assets.
Uniqure |
Banque Pictet Cie SA Decreases Stake in uniQure Defense World
Read at news.google.com
Uniqure NV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Uniqure NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Uniqure NV Fundamental Analysis
We analyze Uniqure NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Uniqure NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Uniqure NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Uniqure NV is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Uniqure NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Uniqure NV stock to make a market-neutral strategy. Peer analysis of Uniqure NV could also be used in its relative valuation, which is a method of valuing Uniqure NV by comparing valuation metrics with similar companies.
Peers
Uniqure NV Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
MGTX | MeiraGTx Holdings | 3.36 | ||||
DAWN | Day One | 1.53 | ||||
RCKT | Rocket Pharmaceuticals | 1.34 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
PCVX | Vaxcyte | 0.38 | ||||
REPL | Replimune | 0.21 | ||||
SLDB | Solid Biosciences | 0.18 | ||||
MRUS | Merus BV | 0.29 | ||||
RYTM | Rhythm Pharmaceuticals | 0.34 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
RNA | Avidity Biosciences | 0.69 | ||||
RGNX | Regenxbio | 0.90 | ||||
KNSA | Kiniksa Pharmaceuticals | 1.08 | ||||
PHAT | Phathom Pharmaceuticals | 1.11 | ||||
STRO | Sutro Biopharma | 1.49 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
GPCR | Structure Therapeutics | 1.78 | ||||
PTGX | Protagonist Therapeutics | 2.56 | ||||
AMLX | Amylyx Pharmaceuticals | 3.48 | ||||
LRMR | Larimar Therapeutics | 4.67 |
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |